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Background and the purpose of the study: The purpose of this study was to prepare pegylated poly
lactide-co-glycolide (PEG-PLGA) nanoparticles (NPs) loaded with roxithromycin (RXN) with appropriate
physicochemical properties and antibacterial activity. Roxithromycin, a semi-synthetic derivative of erythromycin,
is more stable than erythromycin under acidic conditions and exhibits improved clinical effects.
Methods: RXN was loaded in pegylated PLGA NPs in different drug;polymer ratios by solvent evaporation
technique and characterized for their size and size distribution, surface charge, surface morphology, drug loading,
in vitro drug release profile, and in vitro antibacterial effects on S. aureus, B. subtilis, and S. epidermidis.
Results and conclusion: NPs were spherical with a relatively mono-dispersed size distribution. The particle size of
nanoparticles ranged from 150 to 200 nm. NPs with entrapment efficiency of up to 80.0±6.5% and drug loading of
up to 13.0±1.0% were prepared. In vitro release study showed an early burst release of about 50.03±0.99% at 6.5 h
and then a slow and steady release of RXN was observed after the burst release. In vitro antibacterial effects
determined that the minimal inhibitory concentration (MIC) of RXN loaded PEG-PLGA NPs were 9 times lower on S.
aureus, 4.5 times lower on B. subtilis, and 4.5 times lower on S. epidermidis compared to RXN solution. In conclusion
it was shown that polymeric NPs enhanced the antibacterial efficacy of RXN substantially.
Keywords: Roxithromycin, PLGA, Pegylation, Nanoparticles, AntibacterialIntroduction
Infectious diseases were the important reason of death
worldwide at the beginning of the 20th century [1]. An
introduction of antibacterial agents leads to the
decreases in mortality and morbidity from infectious dis-
eases over the last century. These days, though, resist-
ance to antibiotics has been reaching a critical level,
invalidating major antibacterial drugs that are currently
used in the clinic [2,3]. Exploring antibacterial NPs is
one of the new efforts in addressing this challenge, to
which microbial pathogens may not be able to develop
resistance. For instance, in recent studies it has been* Correspondence: dinarvand@tums.ac.ir
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reproduction in any medium, provided the orsuggested that some metal nanostructures are recog-
nized to have antibacterial activities, which is utilized in
controlling infectious diseases [4].
The advantages of NP-based antibacterial drug deliv-
ery include improved solubility of poorly water-soluble
drugs, sustained and stimuli-responsive drug release,
which eventually lowers administration frequency and
dose, and prolonged drug half-life and systemic circula-
tion time. Moreover, minimized systemic side effects via
targeted delivery of antibacterial drugs as well as com-
bined, synergistic, and resistance-overcoming effects via
co delivery of multiple antibacterial drugs can be
achieved using NP carriers [5,6].
Among different nanoparticulate systems, polymeric
NPs have several unique characteristics for antibacterial
drug delivery. Firstly, particle properties such as size,
zeta potentials, and drug release profiles can be precisely
tuned by selecting different polymer lengths, surfactants,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Secondly, polymeric NPs are structurally stable and can
be prepared with a narrow size distribution. Thirdly, the
surface of polymeric NPs can be functionalized by
groups that can be chemically customized with either
drug moieties or targeting ligands [5].
Among the different polymers developed to formulate
polymeric NPs, PLGA has attracted considerable atten-
tion due to its attractive properties: (i) biodegradability
and biocompatibility, (ii) FDA and European Medicine
Agency approval in drug delivery systems for parenteral
administration, (iii) well described formulations and
methods of production adapted to various types of drugs
e.g. hydrophilic or hydrophobic small molecules or
macromolecules, (iv) protection of drug from degrad-
ation, (v) possibility of sustained release, (vi) possibility
to modify surface properties to provide stealth pro-
perties and/or better interaction with biological materi-
als and (vii) possibility to target NPs to specific organs
or cells [7].
Poly ethylene glycol (PEG) has been frequently used
for the surface treatment of polymeric NPs to create a
stealth layer that prolongs the circulation lifetime of NPs
in the blood stream. Specifically, the PEG coating forms
a hydration layer that retards the reticuloendothelial sys-
tem (RES) recognitions of NPs through sterically inhibit-
ing hydrophobic and electrostatic interactions with
plasma proteins [8]. This minimizes the interface with
phagocytic cells and increasing the blood circulation time.
Another attractive characteristic of PEG, with admiration
to its use for mucosal drug administration, is associated
to its mucoadhesion promoting result, a mechanism of
chain penetration across the polymer mucosa interface
may be the reason for this phenomenon.[9].
Roxithromycin (RXN), a semi-synthetic 14-member-
edring macrolide antibiotic derived from erythromycin,
has a molecular weight of 837.06. It possesses improved
pharmacokinetic properties such as high serum concen-
trations and a long half-life of about 13 h. Furthermore,
this it is more resistant to gastric acid hydrolysis. Be-
cause of these properties, together with its spectrum of
activity, RXN appears to offer advantages for the treat-
ment of respiratory tract infections [10] . RXN has bitter
taste and is very slightly soluble in aqueous medium.
The oral bioavailability of RXN is 50% and the low bio-
availability of the drug is mainly due to poor aqueous
solubility and dissolution behavior [11]. Ciprofloxacin
loaded PLGA NPs showed increased antibacterial effect
[12]. In another study, it was reported that rifampicin
loaded PLGA NPs are remarkably more effective against
gram-positive bacteria [13].
In previous study, RXN microspheres with polymers
were prepared successfully by the emulsion solvent dif-
fusion method to cover its bitter taste [14]. Preparationand characterization of complexes of RXN with â-
cyclodextrin (BCD), hydroxypropyl â-cyclodextrin (HPBCD)
to increase the solubility, improve the dissolution proper-
ties and improve the antibacterial activity has been also
reported so as to increase the efficacy of this narrow
spectrum antibiotic [11].
In this study RXN loaded PEG-PLGA NPs were pre-
pared to improve its antibacterial effect. Their physico-
chemical characters, drug release and in vitro antibacterial




RXN powder (USP) was kindly donated by Shifa
PharMed Co, Iran. PLGA (lactide:glycolide, 50:50; Reso-
mer RG 504H, molecular weight 48,000) was purchased
from Boehringer Ingelheim (Ingelheim, Germany). Poly-
vinyl alcohol (molecular weight 22,000) and bifunctional
NH2-PEG-OH (average molecular weight 10000) were
purchased from Sigma-Aldrich (St Louis, MO). 1-Ethyl-
3-(3-dimethylaminopropyl)carbodiimide (EDC), N-
hydroxysuccinimide (NHS), Poly vinyl alcohol (PVA),
with molecular weight of 95,000 from Acros Organics
(Geel, Belgium) and acetone from Merck (Darmstadt,
Germany) were used. Mueller-Hinton broth and
Mueller-Hinton agar (both from Merck) media were
used for microbiological tests. S.aureus (ATCC : 6538) ,
B. subtilis (ATCC : 6633), and S. epidermidis (ATCC :
12228) were obtained from the stock culture of Depart-
ment of Drug and Food Control, Faculty of Pharmacy,
Tehran University of Medical Sciences, Iran. In all
experiments reverse osmosis (RO) purified water was
freshly prepared prior to use. All other materials used
were of analytical or HPLC grade.Synthesis of PEG-PLGA
Hydroxylate functionalized PEG-PLGA was synthesized
by conjugation of OH-PEG-NH2 to carboxylic group of
PLGA [15]. NHS (135 mg, 1.1 mmol) in the presence of
EDC (230 mg, 1.2 mmol) was added to a stirred solution
of PLGA-COOH (5 g, 0.14 mmol) in methylene chloride
(10 mL). The mixture was stirred for 3 hours at 25°C.
PLGA-NHS was precipitated with ethyl ether (5 mL)
and repeatedly washed in an ice-cold mixture of ethyl
ether and methanol to remove the residual NHS. After
drying under vacuum, PLGA-NHS (1 g, 0.059 mmol)
was dissolved in chloroform (4 mL) followed by addi-
tion of NH2-PEG-OH (250 mg, 0.074 mmol) and N,
N-diisopropylethylamine (28 mg, 0.22 mmol). The
copolymer was precipitated with cold methanol after
12 hours and washed with the same solvent (35 mL) to
remove unreacted PEG [15]. The resulting PEG-PLGA
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NP preparation without further treatment. The following
are the main nuclear magnetic resonance (NMR) peaks
of the sample:
1H-NMR (CDCl3 at 300 Hz) d 5.2 (m, (OCH(CH3)C
(O)OCH2C(O)n-(CH2CH2O)m), 4.8 (m, (OCH(CH3)C
(O)OCH2C(O)n-(CH2CH2O)m), 3.7 (s, (OCH(CH3)C
(O)OCH2C(O)n-(CH2CH2O)m), 1.6 (d, (OCH(CH3)C
(O)OCH2C(O))n-(CH2CH2O)m.
Preparation of roxithromycin-loaded pegylated PLGA
nanoparticles
PEG-PLGA NPs loaded with RXN with different ratios
of the drug were prepared by a solvent evaporation
method [16,17]. Briefly, known amounts of polymer and
RXN were added into a mixture of 1 ml DCM:acetone
(3:10), which was suitably stirred to ensure that all ma-
terial was dissolved. This organic phase was emulsified
with 6.7 ml of aqueous solution of PVP (0.5% w/v) by
sonication using a probe sonicator (Misonix S4000-010,
USA) at amplitude 10 for 5 min. NPs were formed im-
mediately, and gently stirred at room temperature for
5 h to evaporate the organic solvent. The resulting NP
suspension was then ultracentrifuged (15,000 rpm for
20 min at room temperature) using a Sigma 3K30 cen-
trifuge. After centrifugation, the NP precipitate was
washed using the same volume of distilled water as the
supernatant, and again centrifuged at 15,000 rpm for
15 minutes. The washing process was repeated three
times in order to remove the adsorbed drugs. To Con-
trol of NP during post-formulation treatment, the size
and drug loading of NP were studied through the stor-
age in solid-state three months after freeze-drying.Particle size and zeta potential measurement
The particle size distribution and poly dispersity index
(PDI) of NPs were determined by Photon Correlation
Spectroscopy (PCS) using a Zetasizer nanoZS (Malvern
Instruments, Worcestershire, UK) at 25°C. Zeta potential
of NPs was also measured by the same instrument. Be-
fore the measurement, all samples were diluted ten
times with deionized water to prevent inter particle ag-
gregation. All the measurements were triplicate and
Mean±SD is reported.
Drug loading and entrapment efficiency
Lyophilized NPs (2.5 mg) were dissolved in 1 mL of
acetonitrile and shaken lightly followed by sonication for
6 minutes. Thereafter, 2 mL of methanol was added to
precipitate the polymer. The sample was filtered and the
drug quantity in the filtrate was determined by high-
pressure liquid chromatography. Drug loading was
determined as the ratio of drug content of NPs to thetotal weight of the NPs. The entrapment efficacy was
obtained as the ratio of the amount of RXN incorpo-
rated in NPs to the amount used for the preparation of
NPs [18]. The experiments were carried out in triplicate.In vitro drug release
The RXN release profile at pH 7.4 in phosphate-buffered
saline and at pH 5.2 in acetate buffer was studied. Five
mg of freeze-dried RXN loaded NPs was poured into
screw-capped tubes and suspended in 10 mL of
phosphate-buffered saline pH 7.4 or acetate buffer pH
5.2. The tubes were placed in a water bath maintained at
37 ± 0.5°C and shaken at 90 cycles/min. At fixed time
intervals, the tubes were taken from the water bath and
centrifuged at 21,000 g for 15 min. The NPs were resus-
pended in 10 mL of fresh buffer and placed back into
the water bath to continue the release measurements.
An aliquot of 9 mL was taken from the supernatant.
A volume of 1 mL of methanol was added to precipi-
tate any remaining PLGA, centrifuged for 15 min at
13255 rpm, and analyzed by high-pressure liquid
chromatography. The experiments were carried out in
triplicate [13].
HPLC analysis was performed at 37°C, using a Knauer
apparatus (model K-1001, WellChrom, Berlin, Germany)
equipped with a reversed-phase C18 column (25 cm ×
0.46 cm internal diameter, pore size 5 μm; Teknokroma,
Barcelona, Spain) and eluted isocratically with Mix 307
volumes of acetonitrile and 693 volumes of a 49.1 g/l
solution of ammonium dihydrogen phosphate adjusted to
PH 5.3 with dilute sodium hydroxide solution. The flow
rate was fixed at 1.5 ml/min and detection was obtained
by UV detection at 205 nm. The linear regression coeffi-
cient determined in the range 0.05–10 μg/ml was 0.9994
(n = 6). The method sensitivity was 0.05 μg/ml (signal to
noise ratio, 3:1) [19].Differential scanning calorimetry (DSC)
DSC was performed to investigate the physical status of
RXN in the NPs. DSC scans of RXN, PEG-PLGA, phys-
ical mixture of PEG-PLGA and RXN and RXN-loaded
NPs were performed on a Mettler DSC 823e equipped
with Mettler STARe system software for the data acqui-
sition. The samples were scanned at a speed of 5°C/min
in a 30–250°C temperature range.Surface morphology
Scanning electron microscopy (SEM, Philips XL 30, Phi-
lips, The Netherlands) was used to determine the shape
and surface morphology of the NPs produced. NPs were
coated with gold under vacuum before scanning electron
microscopy.
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Broth microdilution technique was utilized to determine
the MIC of RXN loaded NPs. RXN solution with the
same concentration of NPs and drug free NPs, prepared
exactly similar to RXN NPs except no drug was added
against S. aureus, B. subtilis, and S.epidermidis were
used as positive and negative control groups. Drug free
NPs were used to ensure the carrier and the ingredients
do not have any antibacterial activity. The bacterium
obtained in lyophilized form which was cultured in Luria
Bertuni agar medium (Scharlau, Spain) after suspending
in sterile distilled water. The plate incubated for 24 h at
37°C. Single colony from the plate was transferred into 4
ml fluid of LB medium and incubated over night at 37°C
and 200 rpm in shaking incubator. The cells were har-
vested by centrifugation at 3000 rpm (Behdad, Iran) for
15 min at 4°C. Subsequently, they were washed twice
and resuspended in Ringer solution to provide the con-
centration range of 105–106 CFU/ml for broth dilution
method (National Committee for Clinical Laboratory
Standards, 1996). A quantity of 12 tubes for each sampleFigure 1 1H NMR spectrum of PEG–PLGA copolymer.and each microbial strain were employed respectively. In
each tube 1ml of medium was placed and was auto-
claved at 121°C for 15 min. After sterilization, 1 ml of
sample was added to the first tube and mixed [13].
Statistical analysis
One-way analyses of variance (ANOVA) were performed
for comparison of the results. A value of P < 0.05 was
considered to be significant.
Results and discussion
Synthesis of PEG-PLGA
In this study PEG-PLGA was synthesized and character-
ized. The basic chemical structure of PEG-PLGA copoly-
mer was confirmed by 1H-NMR (Figure 1). This figure
is very similar to the previously reported spectrum and
confirms the synthesis of the PLGA-PEG copolymer.
One of the prominent features is a peak at 3.7 ppm,
matching the methylene groups of PEG. Overlapping
doublets at 1.6 ppm are attributed to the methyl groups
of the D- and L-lactic acid repeat units. The multiples at
Table 1 Physicochemical characteristics of the roxithromycin nanoparticles
Sample RXN-PLGA (mg) Mean diameter ± SD (nm) PDI ± SD Zeta potential ± SD (mV) Drug loading (%) Entrapment efficiency (%)
S1 4 -25 152±8.4 0.09±0.10 −1.88±0.72 8.8±1.3 64.0±4.2
S2 5 -25 178±6.3 0.13±0.03 −2.63±0.53 10.5±1.1 73.0±3.8
S3 8.2- 25 196±10.5 0.11±0.05 −6.23±2.10 13.0±1.0 80.0±6.5
S4 10 -20 177±6.7 0.09±0.05 −2.48±0.36 11.0±2.1 34.0±5.5
S5 10- 10 181±11.6 0.93±0.12 −4.02±1.64 12.5±1.8 41.0±4.3
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and the glycolic acid -CH, respectively, with the
high complexity of the peaks resulting from different D-
lactic, L-lactic glycolic acid sequences in the polymer
backbone [15].Preparation and characterization of roxithromycin-loaded
nanoparticles
Nanoparticles were prepared by sonication-solvent evap-
oration method. Entrapment efficiencies, drug loading,
size, morphology and zeta potential of RXN pegylated
NPs are reported in the Table 1. As shown in Table 1,
the size of NPs was in the range of 150–200 nm. . In-
creasing the amount of internal phase, containing drug
and polymer, increased the size of nanoparticles. This
may be the result of enhanced viscous forces resisting
droplet break down by sonication. The viscous forces is
in opposition to the shear stresses in the organic phase
and the final finishing size and size distribution of parti-
cles depends on the net shear stress available presented
for droplet breakdown. Narrow range of size distribution
was observed for NPs and the prepared NPs exhibited a
relative monodisperse distribution. As seen in Figure 2,
SEM micrograph of the RXN loaded NPs confirms
that NPs are in spherical shape with smooth surfaces
(Figure 2). All formulations appeared to be homogenous
irrespective of their compositions. The particle size is anFigure 2 SEM micrographs of nanoparticles showing the shape and timportant parameter, as the biopharmaceutical proper-
ties of nanoparticles can be influenced by its physico-
chemical properties. The pegylation of nanoparticles
increases the blood circulation of nanoparticles which
suitable for IV administration [19,20]. The negative zeta
potential of the PLGA nanoparticles tends to limit their
capability to interact with negatively charged plasmids
and intracellular uptake. Pegylation of PLGA helps to
adjust the surface charge of the nanoparticles to become
less negative. In this study, PLGA-PEG NPs showed less
negative zeta potential (−1.9±0.11) than PLGA NPs
(−25.4±0.24). It has been proved that the amount of
phagocytosis is the lowest when zeta potential is closer
to zero [21].
The table also shows an increase in the amount of
PLGA resulted in an increase in the drug entrapment.
This may be attributed to the higher viscosity of the in-
ternal organic phase for higher PLGA ratios, which in
turn would decrease the diffusion coefficient of the drug.
DSC was carried out to investigate the effect of the
process on thermal behavior of formulations [20]. The
DSC scans of samples and the melting point data are
presented in Figure 3. At the mentioned scanning rate
(5°C/min) pure RXN powder had an endothermic peak
at 125°C. However, no melting peak could be detected
for the NP formulations. This shows that DTX in the
NPs is in an amorphous or disordered crystalline phase,
miscible in polymeric NPs. The reduction in enthalpy ofhe surface characteristics of NPs.
Figure 3 DSC thermograms of roxithromycin, PEG-PLGA, physical mixture of roxithromycin and polymer, and roxithromycin loaded
PEG-PLGA nanoparticles.
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ence of smaller amount of drug in the mixture in com-
parison with pure drug.
NPs when freeze dried with sucrose (10% w/w), as
cryoprotectant, were physically stable. No significant
changes in size, zeta potential or drug content wasFigure 4 In vitro roxithromycin release profiles from nanoparticles in
(pH = 7.4, 37°C). Data are represented as mean ± standard deviation (n =detected after freeze dried NPs kept at 4°C for three
months.
In vitro roxithromycin release
The profile of in vitro release of RXN from NPs in
the acetate buffer (pH 5.2) and phosphate-bufferedacetate buffer (pH 5.5, 37°C) and phosphate-buffered solution
3).
Figure 5 Minimum inhibitory concentrations (MICs) (±SD) of
the intact roxithromycin, roxithromycin loaded nanoparticle
and pegylated NPs suspensions against S. aureus (a), S.
epodermidis (b) and B. subtilis (c) (n = 3).
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During the first hours of release, an early burst release
greater than 50% was detected. A slow and steady
release of RXN was observed after the burst release. The
burst release may be due to the release of RXN loadedon the surface or just beneath the surface of the NPs.
Then the sustained release is mainly due to the diffusion
of drug molecules through the polymeric matrix of
the NPs.
Antibacterial activity of the nanoparticle suspensions
The MIC of PEG-PLGA formulations and RXN powder
on S. aureus, B. subtilis, and S. epidermidis are reported
in Figure 5. Drug free polymeric nanoparticles showed
no antibacterial activity which indicates that none of the
ingredients have any antibacterial effect. The MIC of
RXN loaded PLGA NPs were 2.3 times lower on S. aur-
eus, 2.2 times lower on B. subtilis, and 2.4 times lower
on S. epidermidis compared to RXN solution. Conse-
quently, in vitro anti-microbial activity of RXN PLGA
NPs is better than the commercialized drug formula-
tions. Additionally, The MIC of RXN loaded PEG-PLGA
NPs were 9 times lower on S. aureus, 4.5 times lower on
both B. subtilis, and S. epidermidis compared to RXN
solution. The higher antibacterial effect of RXN PLGA
NPs and PEG-PLGA NPs may have been resulted from
higher bacterial adhesion of the NPs. In other studies
enhanced antimicrobial activity from PLGA NPs con-
taining antimicrobial agents has been reported [21,22].
The improved the therapeutic effect of the nanoparticu-
late antibacterial delivery systems may the result of
increased drug concentration nearby its target. More-
over, improved penetration of NPs from biological mem-
branes is also generally accepted. For RXN to be
effective it should pass the bacterial membrane to reach
its intra cellular site of action, subunit 50S of the bacter-
ial ribosome to inhibits the transaction of peptides.
Conclusion
In this study, RXN a semi-synthetic macrolide antibiotic
was successfully loaded into PEG-PLGA NPs. MIC tests
indicated that antibacterial activity of RXN NPs
increased several times compared to RXN aqueous solu-
tion against S. aureus, B. subtilis, and S. epidermidis.
This allows more efficient therapy compared with the
antibiotic in its original form. However, more studies are
necessary to be approved in animals to verify the
pharmacological activities.
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